In the phase II-III, double-blind, randomized RELATIVITY-047 trial, relatlimab (anti-LAG-3) and nivolumab as a fixed dose, compared with nivolumab alone, was evaluated in melanoma patients with unresectable or metastatic disease [105]. The gene discussed is LAG3; the disease is melanoma.